Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space. How has ...

The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial ...

Sentynl Therapeutics secures FDA priority review for CUTX-101, a potential first treatment for Menkes disease. Supported by ...

Administration (FDA) approved an update to the US Prescribing Information (USPI) for Pyrukynd (mitapivat) for the treatment ...

Chinese researchers use AI to identify HG9-91-01, a potential neuroprotective treatment for glaucoma. The molecule shows ...

Patrick Branch, head of Japan and APAC business development at Nxera Pharma, Japan’s most innovative and nimble biopharma ...

Immedica Pharma acquires Marinus Pharmaceuticals for $151 million, gaining the rare disease treatment Ztalmy and expanding ...

Anglo-Swedish drugmaker AstraZeneca has announced that new, positive, long-term results from the pivotal ALPHA Phase III ...

China’s National Medical Products Administration (NMPA) has approved Astellas Pharma’s Vyloy (zolbetuximab), in combination ...

Japanese drugmaker Otsuka Pharmaceutical has announced that the European Medicines Agency (EMA) has accepted for review the ...

Denmark-based macrocycle-drug developer Orbis Medicines today announces the close of a 90 million euros ($94 million) Series ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...